Gu Yan, Chenliang Hong, Weimin Zhu, Qianping Peng, Liu Chong
Clinical Laboratory, Enze Hospital Affiliated to Hangzhou Medical College, Taizhou, Zhejiang, China.
Clinical Laboratory, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
BMJ Open. 2025 Jul 6;15(7):e094490. doi: 10.1136/bmjopen-2024-094490.
Infective endocarditis (IE) is a global public health challenge, and our understanding of its temporal evolution in China compared with the Group of Twenty (G20) countries remains limited. This study aims to analyse the disease burden of IE in China from 1990 to 2021, forecast trends for the next 15 years and compare the findings with those in G20 countries.
Observational study.
The data of 20 countries and regions in G20 were obtained from the Global Burden of Disease (GBD) Study 2021.
Data were publicly available and individuals were not involved.
Using data from the GBD 2021, we collected incidence, disability-adjusted life-years (DALYs) and age-standardised rates for both China and G20 countries. Temporal trends were assessed using the estimated annual percentage change (EAPC) and a joinpoint regression analysis was conducted to pinpoint periods of significant change. Additionally, a decomposition analysis was performed to identify the factors driving changes. Finally, the Bayesian age-period-cohort model was used to forecast trends for the next 15 years.
In 2021, there were 264 282 (95% UI: 216 083 to 315 405) incident cases of IE in China, resulting in 49 925 (95% UI: 38 779 to 69 119) DALYs. The age-standardised incidence rate (ASIR) and age-standardised DALY rate (ASDR) were 14.38 (95% UI: 12.03 to 16.92) and 3.46 (95% UI: 2.65 to 5.01) per 100 000 population, respectively, with both rates being higher in males than in females. Notably, both ASIR and ASDR showed a pattern of first decreasing and then increasing with age, with the highest values observed in the age group of 95 years and above. From 1990 to 2021, the ASIR of IE in China showed a slow upward trend (EAPC: 0.49, 95% CI: 0.44 to 0.55), which was lower than the average level among G20 countries. In contrast, the ASDR exhibited a significant downward trend (EAPC: -6.26, 95% CI: -6.8 to -5.71), representing the largest decline among the G20 countries. The most notable increase in ASIR occurred from 1995 to 2005 in both China and the G20. The greatest decrease in ASDR was observed in China between 2001 and 2004 and in the G20 between 2018 and 2021. Projections suggest that over the next 15 years, the ASIR for both males and females in China will continue to rise, while the ASDR will show a declining trend.
In China, the incidence of IE-related diseases has steadily increased across both genders, despite a declining trend in DALYs. Compared with G20 countries, China's age-standardised burden of IE is relatively low, yet the large increasing number of cases should not be underestimated. Therefore, establishing effective prevention and treatment strategies is crucial to alleviating the future burden of IE.
感染性心内膜炎(IE)是一项全球性公共卫生挑战,我们对其在中国与二十国集团(G20)国家中的时间演变情况的了解仍然有限。本研究旨在分析1990年至2021年中国IE的疾病负担,预测未来15年的趋势,并将研究结果与G20国家进行比较。
观察性研究。
G20中20个国家和地区的数据来自《2021年全球疾病负担(GBD)研究》。
数据为公开可得,未涉及个人。
利用GBD 2021的数据,我们收集了中国和G20国家的发病率、伤残调整生命年(DALYs)和年龄标准化率。使用估计的年度百分比变化(EAPC)评估时间趋势,并进行连接点回归分析以确定显著变化的时期。此外,进行分解分析以确定推动变化的因素。最后,使用贝叶斯年龄-时期-队列模型预测未来15年的趋势。
2021年,中国有264282例(95%不确定区间:216083至315405)IE发病病例,导致49925例(95%不确定区间:38779至69119)伤残调整生命年。年龄标准化发病率(ASIR)和年龄标准化伤残调整生命年率(ASDR)分别为每10万人口14.38例(95%不确定区间:12.03至16.92)和3.46例(95%不确定区间:2.65至5.01),男性的这两个率均高于女性。值得注意的是,ASIR和ASDR均呈现出随年龄先下降后上升的模式,在95岁及以上年龄组中观察到最高值。1990年至2021年,中国IE的ASIR呈缓慢上升趋势(EAPC:0.49,95%置信区间:0.44至0.55),低于G20国家的平均水平。相比之下,ASDR呈现出显著下降趋势(EAPC:-6.26,95%置信区间:-6.8至-5.71),是G20国家中下降幅度最大的。中国和G20中ASIR最显著的上升发生在1995年至2005年。ASDR下降幅度最大的情况在中国是2001年至2004年,在G20是2018年至2021年。预测表明,在未来15年里,中国男性和女性的ASIR将继续上升,而ASDR将呈下降趋势。
在中国,尽管伤残调整生命年呈下降趋势,但IE相关疾病的发病率在两性中均稳步上升。与G20国家相比,中国IE的年龄标准化负担相对较低,但病例数的大量增加不应被低估。因此,制定有效的预防和治疗策略对于减轻未来IE的负担至关重要。